US FDA’s Confidence In Gene Editing Safety Growing Enough That Regulatory Bar May Be Lowered
By Derrick Gingery,
Pink Sheet
| 11. 01. 2023
Some worries about heritable genetic modifications are subsiding and Center for Biologics Evaluation and Research Director Peter Marks said sponsors should consider the US for regulatory advice and clinical trials in the space.
The US Food and Drug Administration’s growing comfort with gene editing has sparked a more relaxed regulatory approach to the products.
Gene editing is a concerning subject for the FDA because the products could unknowingly cause heritable genetic modifications that harm patients. At first, the agency set high safety standards for gene editing trials to proceed in the US.
Center for Biologics Evaluation and Research Director Peter Marks admitted that the bar may have been set too high initially for some gene editing products. But he said that sponsors now should feel more comfortable discussing development plans with the FDA.
“We may adjust the bar a little bit,” Marks told the Pink Sheet on 16 October. “We would like to recalibrate and for people to know that we’re open to consideration and you don’t have to go to another regulator.”
The change in thinking occurred over the...
Related Articles
By Marianne Lamers, NEMO Kennislink [cites CGS' Katie Hasson] | 09.23.2025
Een rijtje gespreide vulva’s gaapt de bezoeker aan. Zó ziet een bevalling eruit, en zó een baarmoeder met foetus. Een zwangerschap, maar dan zonder zwangere vrouw, gestript van zorgen, gêne en pijn. De zwangerschapsmodellen en oefenbekkens, te zien in de...
By Auriane Polge, Science & Vie [cites CGS' Katie Hasson] | 09.19.2025
L’idée de pouvoir choisir certaines caractéristiques de son futur enfant a longtemps relevé de la science-fiction ou du débat éthique. Aujourd’hui, les technologies de séquençage et les algorithmes d’analyse génétique repoussent les limites de ce qui semblait encore impossible. Au croisement...
By Charmayne Allison, ABC News | 09.21.2025
It has been seven years since Chinese biophysicist He Jiankui made an announcement that shocked the world's scientists.
He had made the world's first gene-edited babies.
Through rewriting DNA in twin girls' embryos, the man who would later be dubbed...
By Natalie Ram, Anya E. R. Prince, Jessica L. Roberts, Dov Fox, and Kayte Spector-Bagdady, Science | 09.11.2025
After declaring bankruptcy in March 2025, direct-to-consumer (DTC) genetic testing company 23andMe sold the data of more than 15 million people around the world to TTAM Research Institute, a nonprofit organization created by 23andMe’s founder and long-time CEO. 23andMe’s customers...